Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Genetic factors  (1)
  • Keywords: Brain metastasis; stereotactic radiosurgery; surgery.  (1)
  • 1
    ISSN: 0942-0940
    Keywords: Keywords: Brain metastasis; stereotactic radiosurgery; surgery.
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary  Stereotactic radiosurgery (RS) and surgery have proved to be effective treatment modalities for brain metastasis. We followed 133 patients whose treatment for intracranial disease was either RS or a single surgical resection at the University of Vienna from August 1992 through October 1996. All patients who received additional Whole Brain Radiotherapy were included. This was a retrospective, case-control study comparing these treatment modalities.  Sixty-seven patients were treated by RS and 66 patients were treated by microsurgery. The median size of the treated lesions for RS patients was 7800 mm3, and 12500 mm3 for microsurgery patients, respectively. The median dose delivered to the tumour margin for RS patients was 17 gray.  The median survival for patients after RS was 12 months, and 9 months for patients after microsurgery. This difference was not statistically significant (p=0.19). Comparison of local tumour control, defined as absence of regrowth of a treated lesion, showed that tumours following RS had a preferred local control rate (p〈0.05). Univariate and multivariate analysis showed that this fact was due to a greater response rate of “radioresistant” metastasis to RS (p〈0.005). Postradiosurgical complications included the onset of peritumoural oedema (n=5) and radiation necrosis (n=1). Two patients after microsurgery experienced local wound infection. One postoperative death occurred due to pulmonary embolism in this group.  On the basis of our data we conclude that RS and microsurgery combined with Whole Brain Radiotherapy are comparable modalities in treating single brain metastasis. Concerning morbidity and local tumour control, in particular in cases of “radioresistant” primary tumours, RS is superior. Therefore we advocate RS except for cases of large tumours (〉3 cm in maximum diameter) and for those with mass effect.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 66 (1988), S. 337-339 
    ISSN: 1432-1440
    Keywords: Seminoma ; HLA-association ; Genetic factors ; Pathogenesis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Clinical and epidemiological studies suggest that genetic factors may be involved in the etiology and pathogenesis of testicular germ-cell tumors (GCTs). Previous HLA studies have tried to support the concept of genetic anticipation of GCTs, however, the results obtained have been inconsistent. The reasons for the divergent results are mainly statistical problems, i.e., small patient populations, high numbers of antigens tested, and inhomogeneous study populations. In the present retrospective study, 52 patients with histologically pure seminoma were typed for their HLA-A, B, C, and DR antigens. Only BW41 proved to be significantly increased in frequency after correction for the number of antigens tested (chiQ=12.73;P=0.0005). HLA-DR1 was shown to be decreased, however, the difference was not significant. Regarding metastatic seminoma alone, there was a trend towards an increase of A29, BW41, and DR7. Our study gives only weak evidence for the participation of genetic factors in the pathogenesis of seminoma. The statistical trend of HLA association observed in metastatic seminoma deserves further concern as does the question of whether MHC class II antigens are also involved in the pathogenesis of testicular seminoma.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...